Table 1.
Formulation | DODEG3 (Mol%) | DOPE (Mol%) | DOTMA (Mol%) | CHOL (Mol%) | DODSM (1) (Mol%) | DOSEG3M (2) (Mol%) | |
---|---|---|---|---|---|---|---|
Surface targeted | F1 | 40 | 40 | 10 | 0 | 10 | 0 |
Surface targeted | F2 | 40 | 35 | 10 | 0 | 15 | 0 |
Surface targeted | F3 | 40 | 30 | 10 | 0 | 20 | 0 |
Surface targeted | F4 | 40 | 30 | 20 | 0 | 10 | 0 |
Surface targeted | F5 | 40 | 15 | 10 | 15 | 10 | 0 |
Surface targeted | F6 | 30 | 25 | 10 | 20 | 15 | 0 |
Bimodal | F7 | 40 | 40 | 20 | 0 | 0 | 0 |
Bimodal | F8 | 40 | 20 | 20 | 20 | 0 | 0 |
Surface targeted | F9 | 40 | 40 | 10 | 0 | 0 | 10 |